Bruker Daltonics Announces Selection for Phase II of the ARFCAM R&D Project by the Department of Homeland Security
Bruker Daltonics NBC Detection Corporation announced that it has received a $0.75 million follow-on Phase II contract award for further research and development into the Autonomous Rapid Facility Chemical Agent Monitor (ARFCAM) from the U.S. Department of Homeland Security. ARFCAM is intended to be the next generation chemical agent monitor for government facilities.
Frank Thibodeau, Vice President for NBC Business Development, commented: "This award indicates that Bruker Daltonics has performed well in Phase I and has unique expertise to design and deliver the next-generation technology to help protect our country from the threat of chemical terrorism. This is a challenging program with accelerated timelines and ambitious technical specifications, and we are gratified that the Department of Homeland Security has shown confidence in the ability of Bruker Daltonics to meet these requirements."
Most read news
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
How bacteria maintain and recover their shape
Torsten Olschewski appointed as Business Unit Head at Analytik Jena AG
Better Basics Laborbedarf wins “Best of Industry Award 2024” - “SmartIntegrate” Product Line wins in the Laboratory and Analytical Technology Category
Live-cell microscopy reveals cell migration by direct forces
2BScientific Strengthens Team and Expands Global Supplier Network
Epigenomics AG Forms Medical Advisory Board for Colorectal Cancer Screening - High-profile board to support Epigenomics in development and commercialization of its colorectal cancer screening test in the U.S.
Novel way to identify still unknown pathogens - Evolutionary trade-offs: Balancing genetic disease risks and pathogen protection